NASDAQ:MNKD MannKind (MNKD) Stock Price, News & Analysis $5.37 -0.02 (-0.37%) (As of 11:08 AM ET) Add Compare Share Share Today's Range$5.34▼$5.4250-Day Range$4.75▼$6.0052-Week Range$3.17▼$6.04Volume215,965 shsAverage Volume2.66 million shsMarket Capitalization$1.46 billionP/E Ratio179.06Dividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get MannKind alerts: Email Address MannKind MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside48.4% Upside$8.00 Price TargetShort InterestBearish14.50% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.17Based on 2 Articles This WeekInsider TradingSelling Shares$16,817 Sold Last QuarterProj. Earnings Growth80.00%From $0.10 to $0.18 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.71 out of 5 starsMedical Sector659th out of 924 stocksPharmaceutical Preparations Industry302nd out of 426 stocks 3.5 Analyst's Opinion Consensus RatingMannKind has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMannKind has only been the subject of 1 research reports in the past 90 days.Read more about MannKind's stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted14.50% of the float of MannKind has been sold short.Short Interest Ratio / Days to CoverMannKind has a short interest ratio ("days to cover") of 15.5, which indicates bearish sentiment.Change versus previous monthShort interest in MannKind has recently increased by 7.95%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMannKind does not currently pay a dividend.Dividend GrowthMannKind does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MNKD. Previous Next 1.2 News and Social Media Coverage News SentimentMannKind has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for MannKind this week, compared to 2 articles on an average week.Search InterestOnly 6 people have searched for MNKD on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added MannKind to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MannKind insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $16,817.00 in company stock.Percentage Held by InsidersOnly 3.00% of the stock of MannKind is held by insiders.Percentage Held by Institutions49.55% of the stock of MannKind is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about MannKind's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for MannKind are expected to grow by 80.00% in the coming year, from $0.10 to $0.18 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MannKind is 179.73, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 145.35.Price to Earnings Ratio vs. SectorThe P/E ratio of MannKind is 179.73, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 139.87.Read more about MannKind's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaMassive Crypto Selloff = Historic OpportunityStocks recently suffered the worst 1-day loss since 2022… Cryptos got hammered as well…But here's the fact everyone is missing… As of this writing, Bitcoin is still up 28% year to date…And it's up 84% in the last year. Click here to get details on this opportunity now. About MannKind Stock (NASDAQ:MNKD)MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.Read More MNKD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MNKD Stock News HeadlinesAugust 17, 2024 | finance.yahoo.comMNKD Aug 2024 5.500 call (MNKD240823C00005500)August 14, 2024 | finance.yahoo.comKent Kresa to Retire from MannKind’s Board of Directors; Steven B. Binder to be Appointed to the BoardAugust 22, 2024 | Stansberry Research (Ad)Famous Stock Market Bull Issues Rare “Collapse” WarningTilson says we're in the midst of a collapse – unlike any we've seen since 2008. As you'll see, it all centers around the tech sector. And the epicenter – it turns out – is Apple.August 14, 2024 | globenewswire.comKent Kresa to Retire from MannKind's Board of Directors; Steven B. Binder to be Appointed to the BoardAugust 13, 2024 | americanbankingnews.comMannKind Co. (NASDAQ:MNKD) to Post Q4 2024 Earnings of $0.04 Per Share, Leerink Partnrs ForecastsAugust 7, 2024 | seekingalpha.comMannKind Corporation (MNKD) Q2 2024 Earnings Call TranscriptAugust 7, 2024 | finance.yahoo.comMannKind (MNKD) Q2 2024 Earnings Call TranscriptAugust 7, 2024 | globenewswire.comMannKind Corporation Reports 2024 Second Quarter Financial Results: Provides Clinical Development UpdateAugust 22, 2024 | Stansberry Research (Ad)Famous Stock Market Bull Issues Rare “Collapse” WarningTilson says we're in the midst of a collapse – unlike any we've seen since 2008. As you'll see, it all centers around the tech sector. And the epicenter – it turns out – is Apple.August 5, 2024 | ca.finance.yahoo.comMNKD Aug 2024 8.000 callAugust 5, 2024 | ca.finance.yahoo.comMNKD Aug 2024 5.000 putJuly 31, 2024 | globenewswire.comMannKind Launches Educational Website to Raise Awareness of NTM Lung DiseaseJuly 30, 2024 | globenewswire.comMannKind Corporation to Hold 2024 Second Quarter Financial Results Conference Call on August 7, 2024July 23, 2024 | seekingalpha.comMannKind Corporation: Finally Gaining TractionJuly 17, 2024 | investing.comMannKind Corp EVP sells shares worth over $18,000July 17, 2024 | investing.comMannKind EVP Binder sells shares worth over $16kJune 22, 2024 | globenewswire.comINHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association's 84th Scientific SessionsJune 5, 2024 | globenewswire.comInhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association's 84th Scientific SessionsSee More Headlines Receive MNKD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MannKind and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/07/2024Today8/22/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:MNKD CUSIP56400P20 CIK899460 Webwww.mannkindcorp.com Phone(818) 661-5000Fax661-775-2081Employees400Year Founded1991Price Target and Rating Average Stock Price Target$8.00 High Stock Price Target$10.00 Low Stock Price Target$6.50 Potential Upside/Downside+48.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$0.03 Trailing P/E Ratio179.73 Forward P/E Ratio53.90 P/E GrowthN/ANet Income$-11,940,000.00 Net Margins3.78% Pretax Margin4.59% Return on Equity-3.35% Return on Assets2.08% Debt Debt-to-Equity RatioN/A Current Ratio3.84 Quick Ratio3.57 Sales & Book Value Annual Sales$248.37 million Price / Sales5.91 Cash FlowN/A Price / Cash FlowN/A Book Value($0.91) per share Price / Book-5.92Miscellaneous Outstanding Shares272,316,000Free Float264,147,000Market Cap$1.47 billion OptionableOptionable Beta1.32 Social Links 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Michael E. Castagna Pharm.D. (Age 47)CEO & Director Comp: $1.53MMs. Lauren M. Sabella (Age 63)Executive VP & COO Comp: $1.39MDr. David B. Thomson J.D. (Age 57)Ph.D., Executive VP, General Counsel & Secretary Comp: $862.23kDr. Stuart A. Tross Ph.D. (Age 57)Executive VP and Chief People & Workplace Officer Comp: $739.45kMr. Steven B. Binder (Age 61)Executive Vice President of Special Projects Comp: $854.28kMr. Christopher B. Prentiss M.B.A. (Age 49)Chief Financial Officer Mr. Sanjay Singh M.B.A. (Age 58)Executive Vice President of Technical Operations Comp: $364.53kMs. Rosabel Realica Alinaya (Age 63)VP of Investor Relations & Treasury Comp: $402.26kMr. John F. Bedard (Age 74)Senior Vice President of Worldwide Regulatory Affairs Mr. James Patrick McCauley Jr. (Age 58)J.D., M.B.A., Chief Commercial Officer Comp: $614.06kMore ExecutivesKey CompetitorsAnaptysBioNASDAQ:ANABPhibro Animal HealthNASDAQ:PAHCRadius RecyclingNASDAQ:RDUSOmerosNASDAQ:OMERGossamer BioNASDAQ:GOSSView All CompetitorsInsiders & InstitutionsSusquehanna International Group LLPBought 10,200 shares on 8/16/2024Ownership: 0.000%Creative PlanningBought 39,659 shares on 8/16/2024Ownership: 0.049%Algert Global LLCBought 27,226 shares on 8/16/2024Ownership: 0.010%The Manufacturers Life Insurance Company Bought 3,374 shares on 8/15/2024Ownership: 0.037%AQR Capital Management LLCBought 3,214 shares on 8/15/2024Ownership: 0.016%View All Insider TransactionsView All Institutional Transactions MNKD Stock Analysis - Frequently Asked Questions How have MNKD shares performed this year? MannKind's stock was trading at $3.64 on January 1st, 2024. Since then, MNKD shares have increased by 48.1% and is now trading at $5.39. View the best growth stocks for 2024 here. How were MannKind's earnings last quarter? MannKind Co. (NASDAQ:MNKD) posted its earnings results on Wednesday, August, 7th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.04. MannKind's quarterly revenue was up 48.9% on a year-over-year basis. Who are MannKind's major shareholders? Top institutional shareholders of MannKind include Avoro Capital Advisors LLC (3.22%), Millennium Management LLC (1.74%), TSP Capital Management Group LLC (0.88%) and 180 Wealth Advisors LLC (0.75%). Insiders that own company stock include Michael Castagna, Steven B Binder, David Thomson, Stuart A Tross, Alejandro Galindo and Anthony C Hooper. View institutional ownership trends. How do I buy shares of MannKind? Shares of MNKD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of MannKind own? Based on aggregate information from My MarketBeat watchlists, some other companies that MannKind investors own include Bausch Health Companies (BHC), Novavax (NVAX), Geron (GERN), ACADIA Pharmaceuticals (ACAD), Advanced Micro Devices (AMD), Chesapeake Energy (CHKAQ) and Micron Technology (MU). This page (NASDAQ:MNKD) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredMillionaire Investor Warns: “Brace for Apple Collapse”Apple stock has quadrupled over the past five years. But now even Warren Buffett is pulling the plug. The O...Stansberry Research | SponsoredTrump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Chri...Preserve Gold | SponsoredUS developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will cre...Paradigm Press | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MannKind Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share MannKind With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
